COLD-FX is clinically indicated to help reduce the frequency, severity and duration of cold and flu symptoms.

While flu vaccines are viable preventative measures against specific flu strains, they may not provide protection against all flu strains in the community, nor do they protect from colds or other viruses. Furthermore, the body does not fully develop flu antibodies until approximately 2 weeks after the vaccine is administered, so patients can still be vulnerable to the flu virus for that window of time.

COLD-FX is a way for patients to take a more comprehensive approach in preventing cold and flu symptoms. Here’s what you need to confidently recommend COLD-FX in your practice. Because flu viruses aren’t a one-shot deal.

Active ingredient

Each capsule of COLD-FX is certified to contain a precise amount of CVT-E002TM, a proprietary ChemBioPrint® standardized extract from the root of Panax quinquefolius (North American ginseng, 4:1). As an innate immune modulator, COLD-FX binds to macrophages and dendritic cells, enhancing the body’s immune response. This leads to the enhanced clearance of viruses, resulting in prevention or faster resolution of cold and flu symptoms.

Dosing and administration

COLD-FX is for adults and children 12 years of age and over.

Bottle of COLD-FX capsules

COLD-FX 200 mg

1-2 capsules BID for daily defense throughout cold and flu season

Box containing a bottle of COLD-FX Extra

COLD-FX Extra 300 mg

1 capsule BID for the duration of the cold and flu season.

Significant reduction in the number, severity, frequency and duration of colds in adults aged 18-65.
Graph showing the reduction in the number, severity, and frequency of colds due to COLD-FX use

Randomized, double-blind, placebo-controlled trial conducted from September 2003 to April 2004. Subjects were 18-65 years old, in good general health, with a history of at least 2 colds in the previous year (N=323). Subjects were randomized to receive 2 capsules per day of either a standardized poly-furanosyl-pyranosyl-saccharide extract of the roots of North American ginseng or placebo.

Reduced the risk of upper respiratory infection in vaccinated seniors over a 6-month period

Graph showing the effectiveness of COLD-FX when combined with the flu shot

A 4-month, randomized, double-blind, placebo-controlled trial of 43 community-dwelling adults aged 65 years and older (N=43). Subjects were randomized to receive 2 capsules per day of either COLD-FX 200 mg or placebo. Following one month of intervention, subjects were immunized with influenza vaccine.

Cold and flu news for healthcare professionals

Subscribe to our newsletter to receive important, up-to-date product information, clinical resources and educational opportunities.